News coverage about C.R. Bard (NYSE:BCR) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. C.R. Bard earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the medical instruments supplier an impact score of 46.3892329050288 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

C.R. Bard (BCR) traded down $1.16 during mid-day trading on Thursday, hitting $331.40. 384,688 shares of the company traded hands, compared to its average volume of 661,319. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C.R. Bard has a 1-year low of $218.72 and a 1-year high of $337.73. The firm has a market cap of $24,333.66, a price-to-earnings ratio of 28.83, a PEG ratio of 2.55 and a beta of 0.52.

C.R. Bard (NYSE:BCR) last released its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business had revenue of $989.80 million during the quarter, compared to analyst estimates of $990.64 million. During the same quarter in the previous year, the business earned $2.64 EPS. C.R. Bard’s quarterly revenue was up 5.1% compared to the same quarter last year. sell-side analysts anticipate that C.R. Bard will post 11.89 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a $0.26 dividend. This represents a $1.04 annualized dividend and a dividend yield of 0.31%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s payout ratio is presently 13.70%.

BCR has been the topic of several research analyst reports. Barclays boosted their price target on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Jefferies Group restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a report on Thursday, September 14th. Needham & Company LLC restated a “hold” rating on shares of C.R. Bard in a report on Thursday, October 26th. Cowen restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a report on Friday, November 3rd. Finally, ValuEngine cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a strong buy rating to the stock. C.R. Bard has an average rating of “Hold” and a consensus price target of $303.50.

In related news, insider Timothy P. Collins sold 55,818 shares of C.R. Bard stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $322.03, for a total value of $17,975,070.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Betty D. Larson sold 5,906 shares of C.R. Bard stock in a transaction on Friday, October 20th. The shares were sold at an average price of $330.16, for a total transaction of $1,949,924.96. Following the completion of the sale, the vice president now directly owns 10,753 shares of the company’s stock, valued at approximately $3,550,210.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 210,032 shares of company stock valued at $68,777,261. 0.80% of the stock is owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with Analyst Ratings Network's FREE daily email newsletter.